Menopause is expected to cause symptoms in about 80% of patients. These can vary from mild to very severe and debilitating. The most common are collectively termed vasomotor symptoms (VMS), including ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Sanofi is leading commercialization efforts for Nuvaxovid and Novavax is eligible to receive ongoing tiered royalties from sales of the vaccine. A full 12-month commercial cycle under Sanofi’s control ...

As artificial intelligence continues expansion, a wave of early-stage startups is emerging not to build more powerful models, but to fix growing pains.

BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of ...

Despite the White House’s claim that the platform offers the world’s lowest prices on prescriptions, Democrats on the House Energy and Commerce Committee released a report saying “for nearly half of ...

According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...

Q. My husband got COVID last fall. He has had great success from Paxlovid in the past, when he got it for free during the pandemic. This time he was charged $800 on his Medicare Drug Plan. That seems ...